MRSN Insider Trading
Insider Ownership Percentage: 11.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $154,116.74
Mersana Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Mersana Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Mersana Therapeutics Share Price & Price History
Current Price: $0.31
Price Change: ▲ Price Increase of +0.0495 (18.94%)
As of 04/11/2025 05:00 PM ET
Mersana Therapeutics Insider Trading History
Mersana Therapeutics Institutional Trading History
Data available starting January 2016
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More on Mersana Therapeutics
Volume
2,617,237 shs
Average Volume
2,464,908 shs
Market Capitalization
$38.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.68
Who are the company insiders with the largest holdings of Mersana Therapeutics?